首页|期刊导航|中国食品药品监管|基于风险管理理念设计临床试验数据进展报告

基于风险管理理念设计临床试验数据进展报告OA

Design and Optimization of a Risk-Based Clinical Trial Data Progress Report

中文摘要英文摘要

随着临床试验数据量的迅速增长,数据科学相关人员在数据清理和数据审核过程中面临着前所未有的挑战.本文介绍了基于风险管理的临床数据进展报告设计方案,从数据质量和数据成熟度出发,将数据管理中的风险进行定性与定量分析,并引入统计分析模块,旨在构建多维化风险评估矩阵,提高数据清理和数据审核效率,助力研究团队及时发现特定数据趋势和潜在监查风险,进而优化临床策略的制订.

With the rapid growth in the volume of clinical trial data,data science professionals face increasing challenges in efficiently cleaning and reviewing clinical trial datasets.This paper presents the design of a risk-based clinical data management progress report.Based on two key dimensions(data quality and maturity),the proposed approach performs both qualitative and quantitative analyses of risks in data management and incorporates a statistical analysis module to construct a multidimensional risk assessment matrix.The framework aims to improve the efficiency of data cleaning and review,assist research teams in promptly identifying specific data trends and potential monitoring risks,and ultimately support the optimization of clinical strategies.

李蹊;缪亚东;高坡;王燕;周敏;杨涛;李高扬

映恩生物科技(上海)有限公司正大天晴药业集团股份有限公司凌科药业(杭州)有限公司中山康方生物医药有限公司正大天晴药业集团股份有限公司北京鞍石生物科技股份有限公司羚研创新(北京)健康科技有限公司

医药卫生

临床数据管理数据进展报告基于风险的数据质量监查机器学习数据分析

clinical data managementdata management progress reportrisk-based data monitoringmachine learningdata analysis

《中国食品药品监管》 2026 (3)

84-93,10

国家自然科学基金(81773554)

10.3969/j.issn.1673-5390.2026.03.008

评论